LEADER 01954oam  2200601   450 
001 9910706997503321
005 20190624132607.0
035   $a(CKB)5470000002459498
035   $a(OCoLC)1029561452
035   $a(EXLCZ)995470000002459498
100   $a20180326d2018      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aExamining HRSA's oversight of the 340B Drug Pricing Program $ehearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session, July 18, 2017
210  1$aWashington :$cU.S. Government Publishing Office,$d2018.
215   $a1 online resource (iii, 104 pages) $cillustrations
300   $a"Serial No. 115-46."
320   $aIncludes bibliographical references.
517   $aExamining HRSA's oversight of the 340B Drug Pricing Program 
606   $aPrescription pricing$xGovernment policy$zUnited States
606   $aPoor$xPharmaceutical assistance$zUnited States
606   $aOlder people$xPharmaceutical assistance$zUnited States
608   $aLegislative hearings.$2lcgft
615  0$aPrescription pricing$xGovernment policy
615  0$aPoor$xPharmaceutical assistance
615  0$aOlder people$xPharmaceutical assistance
801  0$bGPO
801  1$bGPO
801  2$bGPO
801  2$bMERUC
801  2$bOCLCF
801  2$bUOK
801  2$bGPO
801  2$bINT
801  2$bGPO
801  2$bOCLCQ
801  2$bOCLCO
801  2$bOCLCA
801  2$bGPO
801  2$bTEU
801  2$bOCLCO
801  2$bIAS
801  2$bOCLCO
801  2$bTXR
801  2$bOCLCO
801  2$bGPO
906   $aBOOK
912   $a9910706997503321
996   $aExamining HRSA's oversight of the 340B Drug Pricing Program$93510702
997   $aUNINA